A Phase Ib/II Trial of AK112 (PD-1/VEGF Bispecific Antibody) in Patients With Advanced NSCLC
Latest Information Update: 26 Mar 2024
At a glance
- Drugs Ivonescimab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Akeso Biopharma
- 22 Mar 2024 According to a Summit Therapeutics Media Release, data from this trial presented at the 2024 European Lung Cancer Congress (ELCC 2024) in Prague, Czech Republic.
- 22 Mar 2024 Results presented In a Summit Therapeutics Media Release.
- 14 Mar 2024 According to Summit Therapeutics media release, data from this study will be presented at the 2024 European Lung Cancer Congress (ELCC 2024) in Prague, Czech Republic.